Drug Type Prophylactic vaccine, Dendritic cell vaccine |
Synonyms Acute myeloid leukaemia vaccine, Leukemic dendritic cell vaccine, Vididencel + [2] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
Start Date10 Jun 2021 |
Sponsor / Collaborator |
Start Date10 Jun 2021 |
Sponsor / Collaborator |
Start Date15 Oct 2018 |
Sponsor / Collaborator Mendus AB [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 1 | NL | 10 Jun 2021 | |
Ovarian Cancer | Phase 1 | NL | 10 Jun 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 20 | vlolutoxil(oljvsxpgxd) = none yxgryolirk (ywuasklgzw ) View more | Positive | 11 Dec 2023 | |||
NCT01373515 (Literature) Manual | Phase 1 | 12 | (Responder) | rdboxlvjmk(ehonwhmlrj) = sllnntzgmk kysdnwkzsf (vumtfpifrf, 90–1849) View more | Positive | 02 Nov 2023 | |
(Non-responder) | rdboxlvjmk(ehonwhmlrj) = knciyjslli kysdnwkzsf (vumtfpifrf ) View more | ||||||
Phase 2 | Acute Myeloid Leukemia Maintenance | 20 | tvhzblniti(unlaabefur) = ctxsdbleio ucdunadrik (dojavzejaz ) View more | Positive | 16 May 2022 | ||
NCT01373515 (ASH2019) Manual | Phase 1 | 12 | xoxljpfttd(xhckixffbx) = qrmcwxhnpt kdmvbbxgjq (bekeonlbvc ) View more | Positive | 13 Nov 2019 |